Blood spot test extended as of 1 January 2017 to include two more disorders As of 1 January 2017, the disorders alpha and beta thalassaemia will be added to the neonatal blood spot (‘heel prick’) screening programme.
EFSA agrees with RIVM that potential effect of BPA on the immune system requires further attention RIVM expressed concerns on the effects of bisphenol a (BPA) on the immune system in a report issued in March 2016.
RIVM recommends more stringent EU standards BPA More stringent European standards for safe exposure of workers and consumers to bisphenol A (BPA) were proposed in 2014 and 2015.
Need for circular use of materials in construction Construction and demolition waste are being recycled on a large scale to use as a foundation for e.g. roads, but recycled building materials are hardly ever used in the construction of buildings.
Measles epidemic and Salmonella outbreak cost nearly six million euros The most recent measles epidemic and outbreak of Salmonella Thomson due to smoked salmon have cost 3.9 and 1.7 million euros, respectively.
Newborn heel prick screening starts on St Eustatius and Saba On 26 October 2015, heel prick screening started for all newborns on St Eustatius and Saba.
CAESAR annual report 2014 The World Health Organization (WHO) published its first CAESAR annual report 2014.
Biobased alternatives to hormone disrupting substance in cash register receipts Chemicals made from vegetable or animal waste may be an alternative to the use of the substance Bisphenol A (BPA) in thermal paper. Thermal paper is widely used for cash register receipts.
RIVM provides overview of the possible risks of bisphenol A RIVM has created an overview of the possible risks of Bisphenol A (BPA) for humans and the environment. BPA is a component of many different products and affects the endocrine system.
No more complementary vaccinations against measles for children aged six months The measles epidemic, the first case of which occurred in the Netherlands in May 2013, is coming to an end.